German therapeutic company ProBioGen has entered a licence and cooperation agreement to grant use of its human lymph node technology in TissUse's multi-organ-chip applications.
ProBioGen’s Human Artificial Lymph Node (HuALN) model will be integrated into the TissUse Multi-Organ-Chip technology.
HuALN was designed as a 3D micro-organoid model for in-vitro analysis of substance effects on the human immune system.
The model is based on a miniaturised and perfused bioreactor, which is inoculated with human blood-derived dendritic cells and T and B lymphocytes. It is also injected with mesenchymal stem cell-derived stromal cells in a 3D hydrogel matrix, which contains cell culture medium and aeration to resemble a human lymph node.
The Lymph Node Model monitors direct effects of substances on the human immune system, while the Multi-Organ-Chip technology mimics various interacting human organs on a device to simulate the human processes over a period of approximately two months.
HuALN analyses the immunofunctions, including immunomodulation, immunogenicity, and immunotoxicity.
TissUse CEO Dr Uwe Marx said: “The combination of ProBioGen’s unique HuALN model and our human Multi-Organ-Chip technology will in future initially allow for the analysis of immunological reactions of human organs on active substances.
“Disease mechanisms in systemic autoimmunological diseases, allergies and anti-tumoural reactions will be elucidated with such Multi-Organ-Chip systems.”
The technology is expected to enable investigation of the body’s reaction to new biopharmaceuticals, vaccines, cosmetics or chemicals without the use of animal testing.
It provides read-outs on the T and B cell level, specifically on cytokine profiles, cell surface markers, cell proliferation, IgM and IgG secretion, anti-drug antibodies, and functional cell tests.